XML 49 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation (Details)
1 Months Ended 3 Months Ended 5 Months Ended 9 Months Ended 12 Months Ended
Jun. 02, 2014
Jun. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
shares
Sep. 30, 2014
USD ($)
May. 31, 2014
USD ($)
Sep. 30, 2015
USD ($)
item
shares
Sep. 30, 2014
USD ($)
Dec. 31, 2011
shares
Stock-based compensation                
Stock-based compensation expense | $     $ 1,468,000 $ 4,732,000   $ 5,223,000 $ 26,013,000  
Number of shares of Theravance Biopharma issued for every share of Theravance 0.286              
Employee Stock Purchase Plan                
Stock-based compensation                
Purchase price as a percentage of fair market value of stock           85.00%    
Consecutive and overlapping offering periods           24 months    
Number of offering periods | item           4    
Duration of purchase period           6 months    
Maximum contributions as a percentage of employee's eligible compensation           15.00%    
Maximum number of shares an employee may purchase during any purchase period           2,500    
Maximum value of shares an employee may purchase | $           $ 25,000    
Shares remaining available for issuance     278,971     278,971    
2012 Equity Incentive Plan                
Stock-based compensation                
Shares remaining available for issuance     3,200,521     3,200,521    
Special Long-Term Retention and Incentive Awards Program | Unvested RSAs | Performance-contingent                
Stock-based compensation                
Shares of common stock approved and authorized for issuance               1,290,000
Timeframe for achievement of performance conditions               6 years
Total stock-based compensation that will be recognized in the year | $         $ 7,000,000      
Stock-based compensation expenses expected to be recognized | $   $ 3,800,000            
RSAs outstanding (in shares)     63,000     63,000